“Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study ”, Ann Med Res , vol. 27, no. 1, pp. 0029–0033, May 2021, Accessed: Apr. 04, 2025. [Online]. Available: http://annalsmedres.org/index.php/aomr/article/view/591